Möhrmann, Lino http://orcid.org/0000-0003-4650-6827
Werner, Maximilian http://orcid.org/0000-0003-0252-5057
Oleś, Małgorzata http://orcid.org/0000-0002-1520-1054
Mock, Andreas http://orcid.org/0000-0002-3332-9166
Uhrig, Sebastian
Jahn, Arne http://orcid.org/0000-0003-1045-1908
Kreutzfeldt, Simon http://orcid.org/0000-0003-3278-4586
Fröhlich, Martina
Hutter, Barbara http://orcid.org/0000-0002-9034-0329
Paramasivam, Nagarajan
Richter, Daniela
Beck, Katja
Winter, Ulrike
Pfütze, Katrin
Heilig, Christoph E. http://orcid.org/0000-0001-8869-1421
Teleanu, Veronica
Lipka, Daniel B. http://orcid.org/0000-0001-5081-7869
Zapatka, Marc
Hanf, Dorothea
List, Catrin
Allgäuer, Michael http://orcid.org/0000-0003-4518-7887
Penzel, Roland
Rüter, Gina
Jelas, Ivan
Hamacher, Rainer http://orcid.org/0000-0001-9655-1226
Falkenhorst, Johanna
Wagner, Sebastian
Brandts, Christian H.
Boerries, Melanie http://orcid.org/0000-0002-3670-0602
Illert, Anna L.
Metzeler, Klaus H. http://orcid.org/0000-0003-3920-7490
Westphalen, C. Benedikt
Desuki, Alexander
Kindler, Thomas
Folprecht, Gunnar
Weichert, Wilko
Brors, Benedikt http://orcid.org/0000-0001-5940-3101
Stenzinger, Albrecht
Schröck, Evelin
Hübschmann, Daniel http://orcid.org/0000-0002-6041-7049
Horak, Peter http://orcid.org/0000-0003-4536-9306
Heining, Christoph
Fröhling, Stefan http://orcid.org/0000-0001-7907-4595
Glimm, Hanno http://orcid.org/0000-0003-4104-1135
Article History
Received: 5 March 2021
Accepted: 6 July 2022
First Online: 2 August 2022
Competing interests
: A.D.: received personal and speakers’ fees, reimbursement for travel and accommodation and honoraria for participance in advisory boards from Astra-Zeneca, Bayer, BMS, Eisei, MSD, Pfizer, Janssen-Cilag, Roche & Servier. A.S.: provided consultation, attended advisory boards, or provided lectures for Astra Zeneca, AGCT, Bayer, Bristol-Myers Squibb, Chugai, Eli Lilly, Illumina, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, F Hoffmann-La Roche, Seattle Genetics, Takeda and Thermo Fisher. A.J.: Honoraria: AstraZeneca. A.L.I.: has attended Advisory Boards and served as speaker for Roche, AstraZeneca, Ars Tempi, Takeda, Janssen-Cilag, AbbVie and Incyte outside of the submitted work. C.B.W.: received personal and speakers’ fees, reimbursement for travel and accommodation and honoraria for participance in advisory boards from Bayer, BMS, Celgene, GSK, Ipsen, MedScape, Merck, Rafael Pharmaceuticals, RedHill, Roche, Servier, Shire/Baxalta, SirTex, and Taiho and scientific grant support by Roche. C.H.: Honoraria: Roche, Novartis; research funding: Boehringer Ingelheim; advisory board: Boehringer Ingelheim. J.F.: Honoraria: Pharmamar, Deciphera; Travel Support: Pharmamar, Eli Lilly outside of the submitted work. L.M.: non-financial support (travel support) from Celgene outside of the submitted work. M.F.: her husband works for Merck KGaA. R.H.: Travel Support: Lilly, Novartis and PharmaMar as well as fees from Lilly and PharmaMar outside of the submitted work. W.W.: has attended Advisory Boards and served as speaker for Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Illumina, Molecular Health, NewOncology and Agilent. W.W. receives research funding from Roche, MSD, BMS and AstraZeneca. S.F.: Consulting or advisory board membership: Bayer, Illumina, Roche; honoraria: Amgen, Eli Lilly, PharmaMar, Roche; research funding: AstraZeneca, Pfizer, PharmaMar, Roche; travel or accommodation expenses: Amgen, Eli Lilly, Illumina, PharmaMar, Roche. The other authors declare no potential conflicts of interest.